Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Sezary Syndrome 1Recurrence 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Nivolumab 7pembrolizumab 4Ipilimumab 4cemiplimab 3Specimen Handling 3relatlimab 2Watchful Waiting 2Standard of Care 2Prednisone 2Phototherapy 2Photochemotherapy 2Melphalan 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Dermoscopy 2Cryotherapy 2Carboplatin 2vedolizumab 1trametinib 1toripalimab 1tirbanibulin 1sulforaphane 1gadopiclenol 1famitinib 1decitabine and cedazuridine drug combination 1daromun 1calcipotriene 1anlotinib 1X-Rays 1Vitamin D 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Aclarubicin × Dermatologic × Clear all
NCT07535710 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma

Shanghai Jiao Tong University School of Medicine

Phase 1/2 Not yet recruiting
37 enrolled
DermatologicLymphoid

Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡